Get access

Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs

Authors

  • A. R. Back,

    Corresponding author
    1. Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA
    • Correspondence address:

      A. Back

      Department of Clinical Sciences

      612 Hoerlein Hall

      College of Veterinary Medicine

      Auburn University

      Auburn, AL 36849, USA

      e-mail: arb0022@auburn.edu

    Search for more papers by this author
  • S. E. Schleis,

    1. Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA
    Search for more papers by this author
  • O. A. Smrkovski,

    1. Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA
    Search for more papers by this author
  • J. Lee,

    1. Comparative Oncology Program, Department of Small Animal Medicine, University of Tennessee, College of Veterinary Medicine, Knoxville, TN, USA
    Search for more papers by this author
  • A. N. Smith,

    1. Comparative Oncology Program, Department of Clinical Sciences, Auburn University, College of Veterinary Medicine, Auburn, AL, USA
    Search for more papers by this author
  • J. C. Phillips

    1. Animal Emergency Critical Care and Referral Center, Knoxville, TN, USA
    Search for more papers by this author

Abstract

Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle. The overall response rate (ORR) to the MOMP protocol was 51.1% for a median of 56 days (range 7–858 days). Twelve percent of dogs experienced a complete response for a median of 81 days (range 42–274 days) and 38.6% experienced a partial response for a median of 49 days (range 7–858 days). Dogs with T-cell lymphoma had an ORR of 55% for a median of 60 days (range 49–858 days) while those with B-cell lymphoma had an ORR of 57% for a median of 81 days (range 7–274 days) (P = 0.783). The overall survival time for all dogs was 183 days (range 17–974 days). Fifty-four percent of dogs experienced toxicity with the majority classified as grade I. The MOMP protocol seems well-tolerated and is an option for dogs with relapsed lymphoma.

Ancillary